Agilent Technologies earnings outlook steady, shares tracked on NYSE
25.06.2026 - 21:36:07 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 21:35.
Agilent Technologies Inc (US00846U1016) remains in focus on the NYSE as investors digest its latest quarterly results and unchanged full-year outlook from late May 2026. The life science tools group continues to emphasize cost discipline and targeted investments in higher-growth segments, according to its earnings materials.
What Agilent reported in May
On 28 May 2026 Agilent reported fiscal second-quarter 2026 revenue of around 1.59 billion US dollars, broadly flat year on year, with core revenue slightly negative but better than some feared, according to its earnings release. The company highlighted that Orders grew modestly in certain life sciences end markets while demand remained mixed across geographies, per the same document. Agilent earnings presentation and Q2 2026 press release
Agilent confirmed its full-year fiscal 2026 outlook at that time, signaling confidence in a gradual recovery in key customer spending while acknowledging ongoing macroeconomic uncertainty. Management reiterated its focus on operating margin resilience and disciplined capital allocation, including continued dividends and selective share repurchases, as set out in its guidance commentary.
How analysts currently view Agilent
Since the Q2 publication several major banks have updated their models on Agilent, with a majority still rating the stock Buy or Overweight and a smaller group recommending Hold, according to recent analyst consensus compilations. Price targets broadly imply upside versus the current NYSE trading level, although some houses have trimmed their targets slightly to reflect a slower recovery in parts of the diagnostics and genomics portfolio. MarketScreener analyst consensus on Agilent
Commentary from Wall Street research desks highlights Agilent’s strong competitive positioning in chromatography, mass spectrometry and laboratory automation, but also notes near-term headwinds from cautious biopharma and industrial customers. Several reports point to potential medium-term benefits from increased investment in cell and gene therapy, advanced materials and environmental testing, areas where Agilent already has established platforms.
All news and analysis on the Agilent Technologies shares
Track the latest corporate disclosures, analyst views and price data for Agilent Technologies in one place.
Where Agilent generates its revenue
Agilent generates most of its revenue by selling analytical instruments, consumables, software and services to laboratories in life sciences, diagnostics, chemical and energy markets. Its portfolio includes chromatography systems, mass spectrometers, automation solutions and genomics tools that support both routine testing and advanced research.
Where the stock trades today
Agilent Technologies stock trades on the NYSE under the ticker A, giving investors exposure to a diversified life science tools and diagnostics business via a large-cap US listing; the latest available price data point comes from regular US trading hours in US dollars.
Agilent Technologies at a glance
- Company: Agilent Technologies Inc.
- ISIN: US00846U1016
- WKN: 929921
- Ticker: A
- Trading venue: NYSE
- Price (as of 2026-06-25, 19:30): 138.50 USD
- Market cap: 40.5 billion USD (as of 2026-06-25)
- Sector / industry: Life Sciences Tools and Services
- Index membership: S&P 500
- Next earnings date: 2026-08-19
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
